WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles:
Related suggestion:
Truck driver who fatally struck 3 Pennsylvania highway workers fell asleep at the wheelRingleader of extreme body modifications cult who made £300,000 from his payPrince Harry heads to airport to leave the UK before Nigeria tour with MeghanRevealed: The key sign that indicates a woman might be a PSYCHOPATHMysterious colorful boxes with letters attached to them wash up on beachesHawaii officials outline efforts to prevent another devastating wildfire ahead of a dry seasonLouisiana court may reopen window for lawsuits by adult victims of childhood sex abuseWhat to know about California's new generative AI toolsIt's not a matter of if a hurricane will hit Florida, but when, forecasters sayRingleader of extreme body modifications cult who made £300,000 from his pay
2.7638s , 6498.015625 kb
Copyright © 2024 Powered by US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition ,Global Gist news portal